

Certificate of Analysis for NR-41898

Klebsiella pneumoniae, Strain BWH 15

Catalog No. NR-41898

Product Description:

Klebsiella pneumoniae (K. pneumoniae), strain BWH 15 was isolated in 2012 from the peritoneal fluid of a human in Boston, Massachusetts, USA. NR-41898 was produced by inoculation of BEI Resources seed lot 70007972 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

Lot: 70061544 Manufacturing Date: 23JUN2023

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided:

E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth mucoid and cream
Motility (wet mount)	Report results	Non-motile
VITEK® 2 MS (MALDI-TOF)	K. pneumoniae	K. pneumoniae (99%)
Antibiotic Susceptibility Profile		
Etest® antibiotic test strips¹		
1 day at 37°C in an aerobic atmosphere on		
Mueller Hinton agar		
Ceftriaxone	Resistant	Resistant (16 µg/mL)
Tobramycin	Sensitive	Sensitive (1 μg/mL)
VITEK® (AST-GN83 Card) ²		
Ampicillin	Resistant	Resistant (≥ 32 µg/mL)
Amoxicillin/clavulanic acid	Resistant	Resistant (≥ 32 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (≥ 32 µg/mL)
Piperacillin/tazobactam	Resistant	Resistant (≥ 128 µg/mL)
Cefazolin	Resistant	Resistant (≥ 64 µg/mL)
Cefuroxime	Resistant	Resistant (≥ 64 µg/mL)
Cefuroxime axetil	Resistant	Resistant (≥ 64 µg/mL)
Cefoxitin	Resistant	Resistant (≤ 4 µg/mL)
Cefotaxime	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Cefepime	Resistant	Resistant (2 µg/mL)
Aztreonam	Resistant	Resistant (≥ 64 µg/mL)
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Amikacin	Sensitive	Sensitive (≤ 2 µg/mL)
Gentamicin	Sensitive	Sensitive (4 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (≤ 0.25 μg/mL)
Nitrofurantoin	Intermediate	Intermediate (64 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to <i>K. pneumonia</i> , strain BWH 15 GenBank: JCNP01000018.1)	99.3% sequence identity to K. pneumonia, strain BWH 15 (GenBank: JCNP01000018.1)

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



Certificate of Analysis for NR-41898

TEST	SPECIFICATIONS	RESULTS
Purity (post-freeze) 7 days at 37°C in an aerobic atmosphere with 5% CO ₂ on Tryptic Soy agar with 5% defibrinated sheep blood	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze)	Growth	Growth

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

/Sonia Bjorum Brower/ Sonia Bjorum Brower

12 SEP 2023

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

 $\mbox{ATCC}^{\circledast}$ is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org Tel: 800-359-7370

Fax: 703-365-2898

²MIC interpretation was determined using VITEK® 2 software version 09.01 combined with the bioMérieux Advanced Expert System™ (AES) software using the interpretation standard CLSI M100-S28 (2018) and the interpretation guideline "Natural Resistance." For more information, please refer to Sanders, C. C., et al. "Potential Impact of the VITEK 2 System and the Advanced Expert System on the Clinical Laboratory of a University-Based Hospital." J. Clin. Microbiol. 39 (2001): 2379-2385. PubMed: 11427542.